摘要
目的探讨血液肿瘤患者血浆纤维蛋白原(Fbg)、D-二聚体(D-D)、抗凝血酶(AT)活性变化及其临床意义。方法应用t检验回顾性分析50例血液肿瘤患者初发、缓解、部分缓解、复发时Fbg、D-D、AT活性水平的差异。结果缓解组、未缓解组、复发组Fbg水平较对照组降低,复发组Fbg水平较缓解组降低,具有显著性差异(P<0.05)。复发组D-D水平较对照组、缓解组及部分缓解组升高,差异具有显著性(P<0.05)。初发组、缓解组、未缓解组、复发组较对照组AT活性显著降低(P<0.05);复发组AT活性较对照组及缓解组降低,具有显著性差异(P<0.05)。结论通过测定Fbg、D-D、AT活性,可评估血液病患者凝血功能,同时可作为判断患者病情变化及预后的一项指标。
Objective To assess the clinical value of fibrinogen （ Fbg）, D- dimer （ D- D） and antithrombin （AT） for leukemia, lymphoma and multiple myeloma patients. Methods 50 hematological malignancy patients were divided into newlydiagnosed group, CR （ complete remission） group, PR （ partial remission） group and PD（progression of disease） group. Clinical data of Fbg, D-D and AT were analyzed retrospectively for these group and normal control group. Results Fbg of CR, PR and PD group were lower than control group. Compared with CR group, Fbg of PD group was decreased （ P 〈 0.05 ）. D- D of PD group became higher than control group, CR and PR group （ P 〈 0.05 ）. AT of newly- diagnosed group and CR, PR, PD group were lower than control group. Compared with control group and CR group, AT of PD group was re- markably decreased （P 〈 O. 05 ）. Conclusion The determination of levels of Fbg, D- D and AT in patients with hematological malignancy maybe important for the evaluation of the effect of treatment and prognosis.
出处
《血栓与止血学》
2010年第1期24-26,共3页
Chinese Journal of Thrombosis and Hemostasis
